“Deja Vu All Over Again”–Monkeypox Edition
Cato Institute's Dr. Jeff Singer (also a member of the ACSH Scientific Advisory Board) - Sometimes it feels as if it’s March 2020 again. Back then I complained that bureaucratic red tape from the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) made Americans wait too long to access COVID-19 tests when they were already widely available in much of the developed world. That made it more difficult to slow the spread of the virus at a time when vaccines and therapeutics were not yet available. Now it appears the FDA and CDC are about to repeat the same mistakes with monkeypox testing and treatment.
In the past, monkeypox outbreaks were rather uncommon, small, and short‐lived outside of the African continent where the virus originated. Because of this, commercial tests have not yet been developed in the U.S. or elsewhere. Increased global travel and trade means that monkeypox will likely become endemic worldwide, increasing the demand for rapid and accurate tests.